Real-world data on the management of pazopanib-induced liver toxicity in routine care of renal cell cancer and soft tissue sarcoma patients.
Kim WesterdijkS D KrensN SteeghsW T A van der GraafE T T L TjwaH WestdorpI M E DesarN P van ErpPublished in: Cancer chemotherapy and pharmacology (2023)
Our study did not demonstrate a clear relationship between pazopanib exposure and the occurrence of pazopanib-induced liver toxicity. Half of the patients were able to safely continue or restart pazopanib treatment after liver toxicity and received the same dose as prior to drug withdrawal. Successful interventions to address pazopanib-induced toxicity in the clinic led to an algorithm for the management of pazopanib-induced liver toxicity.
Keyphrases
- diabetic rats
- high glucose
- oxidative stress
- end stage renal disease
- ejection fraction
- newly diagnosed
- drug induced
- metastatic renal cell carcinoma
- healthcare
- prognostic factors
- peritoneal dialysis
- physical activity
- palliative care
- primary care
- squamous cell carcinoma
- risk assessment
- emergency department
- endothelial cells
- deep learning
- mesenchymal stem cells
- electronic health record
- patient reported
- young adults
- cell therapy
- artificial intelligence
- quality improvement
- chronic pain
- smoking cessation
- stress induced